Proliferating Cell Nuclear Antigen Expression in the Survival of Astrocytoma Patients

     LC Ang, M Plewes, L Tan, H Begley, A Agranovich and D ShulMarc R Del Bigio, Marcia C da Silva, James M Drake and Ursula I Tuor

Abstract:   The PC10, a monoclonal antibody against proliferating cell nuclear antigen (PCNA), is known to show immunoreactivity in routinely processed paraffin embedded tissue. This antibody was applied to 72 astrocytic tumours from surgical biopsy material obtained in a ten year period. The PCNA labelling index (LI) obtained by image analysis was compared with patient's survival, age at diagnosis, and Karnofsky score as well as the histological grade of tumour. The survival analysis shows that patients with tumour PCNA LI of more than 6% have significantly poorer prognosis than those with 6% and below. In addition, there is also good correlation between PCNA LI with age, Karnofsky and tumour grade. This study suggests that although the PCNA expression of astrocytoma could be a useful predictor of patient's outcome, it is not an independent prognostic factor but has derived its statistical association with survival secondarily through its relationship with tumour grade, age and Karnofsky score.

Can. J. Neurol. Sci. 1994; 21: 306-310